Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143997 | 0.83 | SMN1; SMN2 (0.53) | RPS6KA3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13845733 | 0.82 | RAB9A (0.50) | NPC1HPGDRAB9ASMN1; SMN2POLB | |
| SCHEMBL14543365 | 0.82 | RPS6KA3 (0.51) | RPS6KA3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL24510738 | 0.80 | HDAC1 (0.53) | RPS6KA3NPC1RAB9APOLBKDM4E | |
| SCHEMBL14072200 | 0.80 | RPS6KA3 (0.47) | RPS6KA3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14072168 | 0.80 | RPS6KA3 (0.48) | RPS6KA3NPC1HPGDRAB9APOLB | |
| SCHEMBL13845779 | 0.78 | RPS6KA3 (0.48) | RPS6KA3NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14084721 | 0.78 | RPS6KA3 (0.46) | RPS6KA3NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL14072191 | 0.78 | RPS6KA3 (0.47) | RPS6KA3NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL13879891 | 0.78 | RPS6KA3 (0.45) | RPS6KA3HPGDPOLBKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637664-B2 | Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease | SPIROGEN SARL (CH) | 2014-01-28 | — | — | US | disclosed |
| WO-2009060215-A1 | POLYAMIDES | SPIROGEN LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| US-20080214525-A1 | Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease | SPIROGEN LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214525-A1 | Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease | CCNY, NR0B1, CNR1 | RPS6KA3 1609/4885NPC1 1323/4885HPGD 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.